Labrys Biologics Secures $31,000,000 Series A Funding Round

  • Feed Type
  • Date
    1/4/2013
  • Company Name
    Labrys Biologics
  • Mailing Address
    1700 Owens Street San Francisco, CA 94158
  • Company Description
    Labrys Biologics is a private, venture-financed development stage biotechnology company focused on treatments for chronic migraine. Labrys’ lead candidate, RN-307, is an anti-CGRP monoclonal antibody for the treatment of chronic migraine slated to enter Phase 2 clinical trials in 2013.
  • Website
    Undisclosed
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $31,000,000
  • Transaction Round
    Series A
  • Proceeds Purposes
    Under the terms of the agreement with Pfizer, Labrys acquired worldwide rights to RN-307.
  • M&A Terms
  • Venture Investor
    venBio
  • Venture Investor
    Canaan Partners
  • Venture Investor
    InterWest Partners
  • Venture Investor
    Sofinnova Ventures

Next Post

Related Topics

Related Posts

Xconomy Events Across the Network

The Napa Summit 2013: New Rules for Growth

San Francisco · 6/3/13

More Xconomy Events

Xconomy’s Most Popular

  1. Henri Termeer on Startups, Drug Prices, Getting Older (Part 1)
  2. Nine Lessons for Innovators from a Nobel Prize-Winning Psychologist
  3. Xconomy Opens in Texas, Expanding Roundup of Innovation Across U.S.
  4. Life After PowerPoint: Prezi Zooms Ahead in Digital Storytelling
  5. Do You Need an Extended Warranty? Do the Math, Says SquareTrade

Xconomy on Demand

Did you miss something? Don't despair…

Xconomy offers a number of ways to subscribe for free!

Subscribe Now
IDG Tech Network
Protected by Mozy
Eventbrite - events made easy

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit, San Francisco, New York, Boulder/Denver, Texas and beyond.

© 2007-2013, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.

Website development support from Andrew Koyfman with design support from Rob Hunter.